BioPharma Resources

NDA 200063 · Azurity

Contrave

Bupropion Hydrochloride, Naltrexone Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: Nov 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Sep 10, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

440

96 Phase 3, 24 recruiting

FAERS reports

8,503

2,837 serious, 30 with death reported

AI brief across all sources

Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorder and other psychiatric disorders. ( 5.1 ) Monitor for worsening and emergence of suicidal thoughts and behaviors. ( 5.1 ) CONTRAVE is not approved for use in pediatric patients. ( 5.1 ) SUICIDALITY AND ANTIDEPRESSANT DRUGS CONTRAVE ® is not approved for use in the treatment of major depressive disorder or other psychiatric disorders. CONTRAVE contains bupropion, the same active ingredient as some antidepressant medications (including, but not limited to, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, and APLENZIN). Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents,...

What it is approved for

From the label in effect Nov 10, 2025.

CONTRAVE is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition. CONTRAVE is a combination of naltrexone, an opioid antagonist, and bupropion, an aminoketone antidepressant, indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use: The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. ( 1 ) Coadministration with other naltrexone-containing products is not recommended. Coadministration with other bupropion-containing products is contraindicated. ( 1 , 4 ) Limitations of Use: The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. CONTRAVE contains naltrexone and bupropion. Coadministration with other naltrexone-containing products is not recommended. Coadministration with other bupropion-containing products is contraindicated.

Mechanism: CONTRAVE has two components: naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine. Nonclinical studies suggest that naltrexone and bupropion have effects on two separate areas of the brain involved in the regulation of food intake: the hypothalamus (appetite regulatory center) and the mesolimbic dopamine circuit (reward system). The exact neurochemical effects of CONTRAVE leading to weight loss are not fully understood.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CONTRAVE · BUPROPION HYDROCHLORIDE 90MG; NALTREXONE HYDROCHLORIDE 8MG · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bupropion" as an intervention, any sponsor and status, largest first.

All 440 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea1,989
  • headache1,116
  • dizziness1,051
  • vomiting680
  • constipation648
  • feeling abnormal583
  • fatigue526
  • anxiety406
  • insomnia396
  • diarrhoea374
  • drug ineffective368
  • patient dissatisfaction with treatment344

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201413
20151,572
2016832
2017210
2018243
2019308
2020439
2021276
2022355
2023432
20241,327
20252,412
202684

Recalls

2 FDA enforcement reports for this application.

  • Oct 5, 2018 · Class III · Terminated

    Container packaging defect.

  • Aug 9, 2018 · Class III · Terminated

    Defective Container: Customer complaints of punctures in the bottle.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Contrave (Naltrexone HCl/Bupropion HCl)

2024 spending

$1.9M

Beneficiaries

824

2,365 claims

Per beneficiary

$2,315

$4.98 per unit

View as table
YearSpending
2020$71,732
2021$104,905
2022$447,017
2023$1,583,918
2024$1,907,632

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,205 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.